Published on
August 27, 2024
- 10:45 GMT
Adiso Announces Groundbreaking Research Highlighting ADS024 a Novel Oral Agent for Neuroinflammation
A Single Strain Live Biotherapeutic ADS024 Exhibiting LPA3 Agonism in Neuroinflammatory Diseases Featured in Brain, Behavior, and Immunity CONCORD, MA, UNITED STATES, August 27, 2024 /EINPresswire.com/ -- Adiso Therapeutics, Inc. a fully integrated …
Distribution channels:
Banking, Finance & Investment Industry, Business & Economy
...
